BioSyntech Inc (BSY)

[BioSpecialist]

BST-CarGel PIII Results soon . This stock is flying under Radar ..

Positive Final- Data will push this stock over 1$ !!

BioSyntech (BSY.TO)

Market Cap : 10,5 Mio $
Price : 0,10,5 $


BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel® Cartilage Repair Device
June 17, 2009
http://biosyntech.com/en/investors/press.aspx?ID=111


BST-CarGel
http://biosyntech.com/en/expertise/orthopedics/?BST=CarGel


Insider
http://canadianinsider.com/coReport/allTransactions.php?ticker=bsy


Market Potential

BST-CarGel®

Not yet approved by Health Canada, the FDA or the European authorities

BST-CarGel® is aimed at treating focalized cartilage lesions, either from trauma (sports injury or accident) or from secondary osteoarthritis (OA) degeneration.
Arthroscopic view of
a cartlage lesion

The various surgical techniques (microfactures, mosaicplasty, autologous chondrocyte implantation) currently used all have their drawbacks including complicated or multiple surgeries, high cost and/or poor outcomes.

Orthopedic surgeons perform 1.6 million of knee arthroscopic procedures each year in the USA. Cartilage lesions are found in a large number of these procedures.

Additionally, a number of patients too young for arthroplasty, suffering from secondary osteoarthritic focal lesions due to previous trauma, body weight, mis-alignment of the joint or from a previous meniscal surgery, may be good candidates for BST-CarGel®. Osteoarthritis affects around 10% of the population. In the USA alone, it represents 21 million people, out of whom around 65% suffer from OA of the knee.

Cartilage lesions in other joints such as the hip, ankle and the shoulder could potentially benefit from BST-CarGel®.

BST-CarGel® will be more cost-effective than the overly-expensive cell-based therapies to address the challenges of the various healthcare systems around the worl